Clear All
12393 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70121-1754-01 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 15, 2022 Oct 31, 2028 In Use
58468-0357-01 58468-0357 Alemtuzumab Campath 30.0 mg/mL Immunotherapy Monoclonal Antibody CD52 Intravenous Nov 30, 2009 In Use
55513-0710-01 55513-0710 Denosumab Prolia 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jun 5, 2010 In Use
00173-0821-02 00173-0821 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 22, 2011 Aug 31, 2017 No Longer Used
83257-0010-11 83257-0010 Bevacizumab-nwgd JOBEVNE 25.0 mg/mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 10, 2025 In Use
72606-0012-10 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
73042-0201-01 73042-0201 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Nov 25, 2020 In Use
50242-0061-10 50242-0061 Bevacizumab Avastin 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 1, 2019 Feb 28, 2023 In Use
55513-0326-21 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 21, 2025 In Use
00006-5033-02 00006-5033 Trastuzumab Ontruzant 150.0 mg/1 Immunotherapy Monoclonal Antibody HER2 Intravenous Apr 15, 2020 Sep 30, 2023 No Longer Used
57894-0510-01 57894-0510 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 1600.0 mg/10mL, 20000.0 mg/10mL Immunotherapy Monoclonal Antibody EGFR, MET Subcutaneous Dec 19, 2025 In Use
78206-0195-01 78206-0195 Denosumab Bilprevda 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Sep 11, 2025 In Use
00173-0808-02 00173-0808 Ofatumumab Arzerra Immunotherapy Monoclonal Antibody CD20 Oct 26, 2009 Mar 31, 2012 No Longer Used
55513-0160-21 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Apr 30, 2026 In Use
78206-0193-01 78206-0193 Denosumab BILDYOS 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Sep 11, 2025 In Use
72606-0012-01 72606-0012 Bevacizumab-adcd Vegzelma 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 3, 2023 In Use
55513-0160-01 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Dec 18, 2014 In Use
72606-0038-01 72606-0038 Denosumab-bmwo Osenvelt 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jul 2, 2025 In Use
55513-0207-01 55513-0207 Bevacizumab-awwb MVASI 400.0 mg/16mL, 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jun 1, 2018 In Use
55513-0326-01 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan 6, 2021 In Use
70121-2702-01 70121-2702 Denosumab-mobz Boncresa 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Dec 23, 2025 In Use
42747-0761-01 42747-0761 mogamulizumab-kpkc POTELIGEO 4.0 mg/mL Immunotherapy Monoclonal Antibody CCR4 Intravenous Aug 8, 2018 In Use
00024-0656-01 00024-0656 Isatuximab Sarclisa 500.0 mg/25mL Immunotherapy Monoclonal Antibody CD38 Intravenous Mar 2, 2020 In Use
83077-0100-02 83077-0100 Zenocutuzumab BIZENGRI 20.0 mg/mL Immunotherapy Monoclonal Antibody HER2, HER3 Intravenous Dec 4, 2024 In Use
55513-0955-01 55513-0955 Panitumumab Vectibix 200.0 mg/10mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 10, 2006 Feb 28, 2010 No Longer Used

Found 12393 results — Export these results